Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

“Smoldering multiple myeloma” (SMM) is a blood and bone marrow disorder which can lead to multiple myeloma, a deadly cancer.

Saad Z. Usmani, MD, MBA, FACP, discusses how the AQUILA study data presented at ASH 2024, highlighting the benefits of early intervention in high-risk smoldering multiple myeloma, could impact ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

“Smoldering multiple myeloma” (SMM) is a blood and bone marrow disorder which can lead to multiple myeloma, a deadly cancer. Detecting the condition can be a challenge, because those living ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

ROCHESTER, Minn. — A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma ...

SAN DIEGO — The multiple myeloma (MM) drug daratumumab (Darzalex), an anti-CD38 monoclonal antibody, dramatically reduced progression to active MM or death in patients with high-risk smoldering ...

Early interventions with daratumumab reduced progression and prolonged overall survival rate in patients with high-risk ...

SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex ...